- Celcuity (NasdaqCM:CELC) presented updated Phase 1b/2 data for gedatolisib plus darolutamide in mCRPC at ESMO 2026.
- The company reported encouraging clinical activity with progression free survival and a safety profile it described as manageable in this setting.
- Management outlined plans to initiate a Phase 2 study of the gedatolisib and darolutamide combination in metastatic castration resistant prostate cancer.
- The move to Phase 2 for gedatolisib and darolutamide in mCRPC is only one part of Celcuity's story. Take a look at 3 warning signs (2 major) we have identified for Celcuity.
For a wider view on how targeted cancer drugs and data driven treatment approaches are reshaping healthcare, start with 34 healthcare AI stocks.
Celcuity is a US based clinical stage biotech focused on targeted treatments for solid tumors, so the mCRPC program sits squarely within its core oncology effort. For a business with a market capitalization of roughly $3.2 billion, decisions about which combinations progress to later stage trials can meaningfully shape its development pipeline mix.
3 things going right for Celcuity that this headline doesn't cover.
What the mCRPC update really tests in the Celcuity story
The Celcuity narrative asks investors to believe gedatolisib can move from breast cancer into a multi tumor franchise, with prostate cancer as the second pillar, while the business absorbs high upfront spending. This mCRPC readout and planned Phase 2 are an early check on that expansion leg.
Early clinical results in metastatic castration resistant prostate cancer with gedatolisib plus darolutamide, including 6 month radiographic PFS of 67% and generally well tolerated safety, point to a second major tumor area...
See how the full story points towards a $161 fair value for Celcuity.
The new mCRPC data leans toward the bull case that gedatolisib is not a single indication product but a platform therapy that could span breast and prostate cancer. For a company already investing heavily in launch build out, a credible second tumor type helps the long-term revenue story look less dependent on one breast cancer setting.
The same update also underlines bear concerns from the Narrative around execution and funding risk. Moving into Phase 2 in mCRPC adds another costly program on top of VIKTORIA trials and the Revtorpyk launch, while competitors like Novartis and Pfizer continue to push their own targeted prostate and breast regimens, which could pressure future share of that opportunity.
In the end, this news only matters to you in the context of whether you buy the broader Celcuity story about gedatolisib becoming a multi indication engine rather than a one product bet.
Add Celcuity to your Watchlist and get alerts as these catalysts play out.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com